Clinical trial Recruiting at 1 site Interventional Ages 18 and up

Chatbot support program to improve well-being of caregivers of children with autism

Official title: A Chatbot-based Program to Promote Well-being in Caregivers of Children With Autism Spectrum Disorder

Run by Hong Kong Metropolitan University · NCT07059013 · Data updated 2026-11-12

This program will try a chatbot to improve mental well-being for caregivers of 6–11 year-old children with autism.

More Autism Spectrum Disorder trials

Quick facts

Study typeInterventional
Ages18 Years and up
SexAll
Enrollment130 (estimated)
SponsorHong Kong Metropolitan University
Academic / other
Locations1 site (Hong Kong)
StatusRecruiting
StartedAugust 15, 2025
Main results expectedMay 31, 2026
Study endsJuly 31, 2026
Registry record updatedDecember 17, 2025
Trial IDNCT07059013 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Primary caregivers aged 18 or older of a child aged 6–11 with a clinician-confirmed diagnosis of ASD who can read Chinese and agree to complete questionnaires at three time points.

Probably not a fit

Caregivers with severe psychiatric disorders or cognitive impairment, those who received a similar psychological intervention within the past year, or those unable to read Chinese or use a chatbot are unlikely to benefit.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This interventional program uses a chatbot-based intervention offered by Hong Kong Metropolitan University to support the mental well-being of primary caregivers of children with autism aged 6–11. Eligible caregivers must be 18 or older, able to read and communicate in Chinese, and provide documentation of their child’s clinician-diagnosed ASD. Participants will interact with the chatbot and complete questionnaires at three time points to measure changes in stress, mood, and coping. People with severe psychiatric disorders, cognitive impairment, or recent participation in a similar psychological intervention are excluded.

Why it matters

Potential benefit: If successful, the chatbot could reduce caregiver stress and improve mood and coping while making psychological support easier to access.

How similar studies have gone: Some digital mental-health programs have shown benefit for caregivers, but chatbot-specific support for caregivers of children with ASD is relatively new and not yet widely proven.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* caregivers providing long-term care for the children with a diagnosis of ASD from a qualified clinician, confirmed through the provision of documentation by the parents;
* caregivers of primary-school-age child (6-11 years old) (this age range is selected because social and communication interaction of children with ASD may be progressively more awkward in this age range when the social demands become more prominent);
* caregivers who are over 18 years old;
* caregivers who have the ability to communicate and read in Chinese;

Exclusion Criteria:

* Unwilling to complete the questionnaires at 3 time points;
* Diagnosis of severe psychiatric disorder (such as schizophrenia and severe bipolar disorder) or cognitive impairment;
* Participation of a similar psychological intervention within one year.

Where it's running

  • Hong Kong Metropolitan University
    Hong Kong, Hong Kong
    Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.